Just to put things in perspective the events from the 1st of October 2009 (highlighted in bold) until the 17th of march 2010 (highlighted in bold) had shot OBJ to 6cents or above on three occasions. In hindsight the events that unfolded still pointed to very early stage developments between OBJ and its respective companies. The events that followed the 'response to query' led to the share price dipping all the way down to our recent low of 1.1cents This company is now clearly undervalued, we peaked at 6.7cents so that should be our minimum share price at the moment considering the progress that the company has made and the scope of its technology applications... Bring on 2013!
09' -ETP patch testing -EM patch tooth strip study results -Tooth strip attracts industry interest resulitng in multiple potential partners -Company in discussions with several international dermatology companies -Company announces the companies transition from research t product deveopment and ultimately commercialisation -US study results released -OBJ enters MTA with 3M
10' -Extension of MTA -FMCG statement of intent -GSK enters into further agreement with OBJ -Asx response to query -OBJ expands from drug delivery for the pharmaceurtical and therapuetic markets into larger consumer and homecare markets using physical rather than chemical technologies -Company engages number of international companies across variety of product sectors in USA Europe and UK. Leading brand name corporation in field of non-prescription therapeutics, oral health, skin care, cosmetics and haircare. -FIM technology announced -6new IP's are lodged
11' -First in man studies being finalised between OBJ and GSK -FMCG2 progresses across multiple fronts "broad range of products for which OBJ is being evaluated". University study shows significant increased in the delivery of key anti-ageing ingredient through stratum corneum. -FMCG1 moved from a number of stages of technical evaluation to consumer studies and was then being reviewed by the international marketing department. Interest from within FMCG1 has created further potential product development opportunities. -Expansion of presense in UK -CDA with GSK to develop new oral health products utilising FIM and ETP technologies Objective being to develop and commercially release the products. -OBJ's own pain patch development program announced -US patent office allows dermaportation patent -Global FMCG to secure access rights for beauty care -US patent granted
12' -GSK expands scope of current collaboration to include additional key oral health active ingredients. -Micro needles announced for the first time-correct me if im wrong here -Knee guard moves a step further during the quarter. Market research indicating commercial opportunity for the company in both retail anagesic and sporting markets -P&G enters JDA. Exclusice multi-product JDA "P&G partnership directly aligns with P&G's business strategies, working to develop new solutions and innovations that can touch and improve the lives of our consumers all over the world" Jeff weedman P&G's vice president of global business development. -First program set out in JDA advances to next stage whilst a second program involving a new P&G nominated molecule enters development by our R&D team -Successful OBJ sponsored ex vivo studies for oral health ingredients used in the treatment of teeth hypersensitivity and tooth demineralisation.
OBJ Price at posting:
1.9¢ Sentiment: Hold Disclosure: Held
(20min delay)